3.3 Corticosteroids and MACE at long-term follow-up.
Among patients with hs-cTnT >0.014 µg/L, corticosteroid-treated patients showed a lower incidence of MACE than untreated ones [29% (29/99) vs. 43% (92/213); p=0.042] during the follow-up (Figure 3).
A COX regression analysis confirmed that in-hospital corticosteroid use was inversely associated to MACE (HR: 0.64; 95% CI: 0.41-0.97; p=0.038), while age (HR: 1.05; 95% CI: 1.03-1.08;p<0.001); CHD (HR: 1.6; 95% CI: 1.05-2.33; p=0.029); congestive heart failure (HR: 1.72; 95% CI: 1.15-2.58; p value =0.009) were positively associated to MACE, after adjusting for sex, smoking habit, COPD, arterial hypertension, CKD, diabetes, history of stroke, PAF and CAF.
Among patients with hs-cTnT≤0.014 µg/L, the incidence of MACE did not differ in patients treated or not with corticosteroids (14% vs. 7%; p value =0.222).